Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How are you integrating Prostox into your practice for prostate patients deciding between SBRT and hypofractionation?
Related Questions
How would you treat an isolated urothelial cancer local recurrence abutting the duodenum?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
How do you incorporate absolute percent pattern 4 (APP4) into your risk stratification, specifically your recommendation for ADT for intermediate prostate cancer?
How long would you delay prostate radiation following use of a paclitaxel-eluting balloon dilator (optilume) for management of a recurrent urethral stricture after TURP?
What duration androgen deprivation do you recommend with salvage pelvic radiotherapy for pelvic node relapse after prostatectomy?
How do you manage a prostate cancer patient with pelvic lymphadenopathy and a single enlarged PSMA PET+ gastrohepatic node?
Would you consider re-irradiation for a prostate local failure for a patient who initially received standard fractionation with a focal SIB to 95 Gy, or a SBRT boost with cyberknife after EBRT?
How do you manage bladder spasms during pelvic radiotherapy?
Would you offer re-irradiation for a prostate local recurrence after I-125 seed implant >10 years ago in a healthy young patient with life expectancy >15 years?
Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?
